Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.
Makhlin I, McAndrew NP, Wileyto EP, Clark AS, Holmes R, Bottalico LN, Mesaros C, Blair IA, Jeschke GR, Fox KR, Domchek SM, Matro JM, Bradbury AR, Feldman MD, Hexner EO, Bromberg JF, DeMichele A.
Makhlin I, et al. Among authors: holmes r.
NPJ Breast Cancer. 2022 Nov 11;8(1):122. doi: 10.1038/s41523-022-00487-x.
NPJ Breast Cancer. 2022.
PMID: 36369506
Free PMC article.